Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
NCT06066125 is registered in ClinicalTrials.gov with Akeso as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
- Lead sponsor
- Akeso
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2023
- Completion date
- August 19, 2024
- Enrollment
- 351 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.